Organon & Co.

Traded on the St. Petersburg Stock Exchange
Organon & Co. is an American pharmaceutical company that specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, Hormone replacement therapy (HRT), and anesthesia. It was incorporated in 2020 and is based in Jersey City, New Jersey.
Organon & Co. stock price chart
vol.
change
P/E adj.
Net profit (adj.)
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Organon & Co. balance sheet

Report period20192020 2021 20222023
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Organon & Co. cash flows

Report period20192020 2021 20222023
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
Adjusted Earnings
EBITDA
Adjusted EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS
Adjusted EPS

Organon & Co. multipliers

Report period20192020 2021 20222023
P/E
P/E adj.
E/P
E adj./P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
Net Debt/EBITDA adj.
EV/EBITDA
EV/EBITDA adj.

Organon & Co. profitability

Report period20192020 2021 20222023
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Organon & Co. assets
Organon & Co. cash flows
Organon & Co. dividends
6.53%

Organon & Co. dividend policy

The company doesn't provide dividends

Organon & Co. shares

TickerNameTypeNominal valueISINPrice
OGN:USOrganon & Co.Common share-US68622V1061$17.82
Organon & Co. news
05.05.2022
The Organon & Co. Board of Directors announced a quarterly dividend of $0.28 per share. The last day to buy securities to receive the dividend is May 12, 2022. The annual dividend yield may reach 3.28%.
05.05.2022
Organon & Co. reported GAAP net income of $348 million for the first 3 months of 2022, down 12.8% from $399 million in the previous year. Revenues rose 4.1% to $1.567 billion from $1.506 billion a year earlier.
17.02.2022
Organon & Co.'s GAAP net income for 2021 was $1.351 billion, down 37.5% from $2.16 billion the previous year. Revenue declined 3.5% to $6.304 billion from $6.532 billion a year earlier.
18.01.2022
The Organon & Co. Board of Directors announced a quarterly dividend of $0.28 per share. The last day to buy securities to receive the dividend is February 24, 2022. The annual dividend yield may reach 2.48%.
General information
Company nameOrganon & Co.
Tags#pharmacy, #s&p500 index
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals / Pharmaceuticals
Business address30 Hudson Street Jersey City, NJ 07302 United States
Mailing address30 Hudson Street Jersey City, NJ 07302 United States
Websitewww.organon.com
Information disclosurewww.sec.gov